NEW YORK (TheStreet) -- CHANGE IN RATINGS
Carefusion (CFN) was downgraded at Goldman to sell from neutral. Valuation call, based on a $36 price target.
Catamaran (CTRX) was downgraded at Goldman Sachs to neutral from buy. Company was also cut from the Conviction List. $50 price target. Valuation call, based on a lower growth outlook, Goldman said.
Eastman Chemical (EMN) was initiated at UBS with a buy rating. Expected to deliver double-digit growth, UBS said. $92 price target.
Domino's Pizza (DPZ) was upgraded to buy at TheStreet Ratings.
Finish Line (FINL) was upgraded at Bank of America/Merrill Lynch to buy from underperform. $30 price target. Pipeline is improving and Macy's deal should help drive growth, BofA/Merrill said.
Haemonetics (HAE) was downgraded at Goldman Sachs to sell from neutral. $39 price target. Company faces growth headwinds, Goldman said.
Medtronic (MDT) was upgraded at Goldman Sachs to buy. $66 price target. Organic growth should accelerate over the next several quarters, Goldman said.
Midcoast Energy Partners (MEP) was initiated at UBS with a buy rating. Pure play on Enbridge Energy Partners' G&P assets, UBS said. $23 price target.
Stifel Financial (SF) was upgraded to buy at TheStreet Ratings.
Stock Comments / EPS Changes
Avago Technologies (AVGO) price target was increased at UBS. The company lifted its numbers, UBS said. Driven by accretive acquisition of LSI, UBS said. $60 price target and buy rating.
Hess (HES) was added to the US1 List at Bank of America/Merrill Lynch. Company is buying back more stock and could separate the retail business in 2014, BofA/Merrill said.
Westport Innovations (WPRT) price target, EPS estimates were lowered at Jefferies. Bumps in the road driven by likely low order trends and challenging environment to execute, Jefferies said. $28 price target and buy rating.
Follow TheStreet on Twitter and become a fan on Facebook.